News

The drug was pulled form the shelves after reports about the drug’s possible side effects were published. The reports suggested that the drug could cause heart valve regurgitation.

If approved for marketing by the FDA, Provenge would become the first active cellular immunotherapy and the first biologic approved to treat prostate cancer. The FDA will now

Globorix is designed to treat diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Neisseria meningitides serogroups A and C. Globorix will only be sold and used in

If licensed, the vaccine will be indicated for the prevention of cervical cancer and precancerous lesions associated with the most common cancer-causing human papillomavirus types. For this candidate

Reverse genetics is a method by which viruses such as influenza can be generated entirely from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be

The phase I/II study indicated that Baxter’s H5N1 candidate vaccine is highly immunogenic at low doses, and induces substantial levels of cross immunity against widely divergent H5N1 strains.

Clinical Data said it plans to offer the 454 GS FLX ‘Next Generation’ sequencing technology as a fee-for-service offering to clients worldwide and has said it will collaborate

The company plans to use this technology to develop an oral liquid product of its chronic pain drug Kadian. Alpharma said this planned addition to the Kadian product

NeoPharm said it was disappointed by the decision which, if implemented, would significantly delay the introduction of this therapy to the market. However, the Office of Oncology has